title: Using daptomycin in hospitalised patients with cSSTI caused by Staphylococcus aureus has an impact on costs.
abstract: BACKGROUND
  The aim was to assess the cost impact of daptomycin compared to vancomycin treatment in patients hospitalised for complicated skin and soft-tissue infection (cSSTI) with suspected methicillin-resistant Staphylococcus aureus infection in the UK.
  
  
  METHODS
  A decision model was developed to estimate the costs associated with cSSTI treatment. Data on efficacy, treatment duration and early discharge from published clinical trials were used, with data gaps on standard clinical practice being filled by means of clinician interviews.
  
  
  RESULTS
  Total health-care costs per patient were GBP 6,214 and GBP 6,491 for daptomycin and vancomycin, respectively. A sensitivity analysis suggested that modifying the parameters within a reasonable range does not impact on the conclusion that the higher cost of daptomycin is likely to be offset by lower costs of monitoring and hospitalisation.
  
  
  CONCLUSIONS
  This study demonstrates that daptomycin not only provides an alternative treatment for multiple resistant infections, but may also reduce National Health Service costs.
authors: Evidera, London, UK.
authors: Noemi
authors: N
authors: Muszbek
authors: Ruth
authors: R
authors: Chapman
authors: Chantelle
authors: C
authors: Browne
authors: Kevin
authors: K
authors: Marsh
authors: Ian M
authors: IM
authors: Gould
authors: Ruth E
authors: RE
authors: Brown
authors: Maria-Magdelana
authors: MM
authors: Balp
authors: Mike
authors: M
authors: Allen
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017576:Daptomycin / Q000627:therapeutic use*; D017048:Health Care Costs; D006760:Hospitalization; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000302:isolation & purification; D018803:Models, Economic; D010361:Patients; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D013211:Staphylococcus aureus / Q000302:isolation & purification*
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin